NeuroLens scores $80M Series B to commercialize EEG-driven UX personalization

AI · 4 min read

NeuroLens, a company that couples lightweight EEG headbands with machine learning to infer attention, stress, and engagement signals, announced an $80 million Series B led by HealthTech Growth Partners. The company will use the funding for clinical trials, device miniaturization, and SDK improvements for enterprise customers.

NeuroLens offers an SDK that maps real-time neural signals to UX adaptations—adjusting content density, notification timing, or interface complexity based on inferred cognitive state. Early pilots in teletherapy and e-learning showed improved retention and reduced user churn when interfaces adapted to user attention patterns.

The startup is aware of privacy and ethical concerns and says it will implement strict local processing defaults and explicit consent flows. NeuroLens plans to ship an enterprise-grade headset that integrates with workplace wellness suites and a developer sandbox for non-clinical experimentation.